13F filer · CIK 1892770
Knott David M Jr
SYOSSET, NY · filing since Q4 2021 · last filing Aug 12, 2026
Reported value
$189.2M
+$21.1M vs prior
Positions
84
New / sold out
11 / 12
Added / reduced
16 / 4
Turnover
6.3%
buys $11.3M · sells $12.9M
Top-10 weight
62.8%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Catalyst Pharmaceuticals, Inc. | +114,000 | – | +$3.6M |
| New | Spruce Biosciences, Inc. | +20,000 | – | +$1.1M |
| Added | Cullinan Therapeutics, Inc. | +44,982 | +185.9% | +$819.1K |
| Added | Madrigal Pharmaaceuticals, Inc. | +1,000 | +50.0% | +$537.0K |
| New | DuPont de Nemours, Inc. | +3,767 | – | +$511.0K |
| New | Insmed Incorporated | +4,253 | – | +$453.5K |
| New | LB Pharmaceuticals, Inc. | +12,965 | – | +$420.8K |
| New | CareDx, Inc. | +13,630 | – | +$388.5K |
| New | Q32 Bio Inc | +30,412 | – | +$387.4K |
| Added | Travere Therapeutics, Inc. | +6,649 | +4.7% | +$377.7K |
17 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Catalyst Pharmaceuticals, Inc. | -120,000 | -100.0% | $-3.0M |
| Sold out | Arcellx Inc | -19,433 | -100.0% | $-2.2M |
| Sold out | Cytokinetics, Incorporated | -23,644 | -100.0% | $-1.6M |
| Sold out | Centessa Pharmaceuticals PLC | -39,000 | -100.0% | $-1.5M |
| Reduced | TG Therapeutics, Inc. | -23,162 | -25.7% | $-1.3M |
| Reduced | Bristol-Myers Squibb Company | -11,622 | -85.3% | $-669.7K |
| Sold out | ADMA Biologics, Inc. | -60,200 | -100.0% | $-542.4K |
| Sold out | Biohaven Pharmaceutical Holding Co. Ltd | -60,720 | -100.0% | $-513.7K |
| Reduced | JPMJPMorgan Chase & Co. | -1,379 | -7.1% | $-451.4K |
| Sold out | Evolus, Inc. | -99,338 | -100.0% | $-408.3K |
6 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Alphabet Inc-Cl CCOMMON | 91,420 | $32.3M | 17.07% |
| 2 | Apollo Global Management, Inc.COMMON | 225,000 | $26.6M | 14.07% |
| 3 | Syndax Pharmaceutical, Inc.COMMON | 437,245 | $9.6M | 5.05% |
| 4 | Xeris Biopharma Holdings, Inc.COMMON | 1,060,000 | $8.4M | 4.44% |
| 5 | Travere Therapeutics, Inc.COMMON | 147,282 | $8.4M | 4.42% |
| 6 | Protagonist Therapeutics, IncCOMMON | 63,000 | $7.7M | 4.08% |
| 7 | Bridgebio Pharma, Inc.COMMON | 92,850 | $6.9M | 3.66% |
| 8 | Iovance Biotherapeutics, Inc.COMMON | 1,600,000 | $6.7M | 3.52% |
| 9 | Alkermes PLCCOMMON | 121,759 | $6.4M | 3.37% |
| 10 | JPMJPMorgan Chase & Co. | 18,098 | $5.9M | 3.13% |
74 more rows. Subscribe for $29/month to see every row, download the data and use the API.